Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.
Sofia C TorresMaureen TrudeauSonal GandhiEllen WarnerSunil VermaKathleen I PritchardTeresa PetrellaMark Hew-ShueCalvin ChaoAndrea F EisenPublished in: The oncologist (2018)
This is the first decision impact study to include exclusively women with ER-positive, HER2-negative, early-stage breast cancer with 1-3 positive lymph nodes, a population typically treated with adjuvant chemotherapy. This study provides evidence that, in these patients, the Oncotype Dx Recurrence Score assay influences systemic treatment decisions. Most of the changes in treatment recommendation resulted in withdrawal of chemotherapy or change in recommendation from a chemotherapy regimen with anthracyclines to a taxane-only regimen. If prospective studies confirm that these decisions result in good outcomes, a reduction in the use of chemotherapy might result in pharmacoeconomic savings.
Keyphrases
- early stage
- lymph node
- positive breast cancer
- high throughput
- newly diagnosed
- locally advanced
- squamous cell carcinoma
- type diabetes
- ejection fraction
- combination therapy
- gene expression
- adipose tissue
- sentinel lymph node
- decision making
- dna methylation
- patient reported outcomes
- chemotherapy induced
- endoplasmic reticulum